JP2013503621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503621A5 JP2013503621A5 JP2012527383A JP2012527383A JP2013503621A5 JP 2013503621 A5 JP2013503621 A5 JP 2013503621A5 JP 2012527383 A JP2012527383 A JP 2012527383A JP 2012527383 A JP2012527383 A JP 2012527383A JP 2013503621 A5 JP2013503621 A5 JP 2013503621A5
- Authority
- JP
- Japan
- Prior art keywords
- lrg1
- antagonist
- seq
- tumor
- interaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 33
- 230000003993 interaction Effects 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 9
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 claims 7
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 claims 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108010033276 Peptide Fragments Proteins 0.000 claims 5
- 102000007079 Peptide Fragments Human genes 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 108091005735 TGF-beta receptors Proteins 0.000 claims 4
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 101000783723 Homo sapiens Leucine-rich alpha-2-glycoprotein Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0915515.1A GB0915515D0 (en) | 2009-09-04 | 2009-09-04 | Treatment of vasculoproliferative conditions |
| GB0915515.1 | 2009-09-04 | ||
| PCT/GB2010/001681 WO2011027129A1 (en) | 2009-09-04 | 2010-09-06 | Treatment of vasculoproliferative conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015241950A Division JP6242847B2 (ja) | 2009-09-04 | 2015-12-11 | 血管増殖性疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503621A JP2013503621A (ja) | 2013-02-04 |
| JP2013503621A5 true JP2013503621A5 (enExample) | 2013-10-24 |
Family
ID=41203240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527383A Pending JP2013503621A (ja) | 2009-09-04 | 2010-09-06 | 血管増殖性疾患の治療 |
| JP2015241950A Active JP6242847B2 (ja) | 2009-09-04 | 2015-12-11 | 血管増殖性疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015241950A Active JP6242847B2 (ja) | 2009-09-04 | 2015-12-11 | 血管増殖性疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8790647B2 (enExample) |
| EP (1) | EP2473526B1 (enExample) |
| JP (2) | JP2013503621A (enExample) |
| CN (1) | CN102596998B (enExample) |
| AU (1) | AU2010290986B2 (enExample) |
| CA (1) | CA2771965C (enExample) |
| ES (1) | ES2647359T3 (enExample) |
| GB (1) | GB0915515D0 (enExample) |
| WO (1) | WO2011027129A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5717021B2 (ja) * | 2009-12-03 | 2015-05-13 | 独立行政法人医薬基盤研究所 | 血管新生誘導分子 |
| WO2013132267A1 (en) | 2012-03-09 | 2013-09-12 | Ucl Business Plc | Treatment of cancer |
| TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
| JP6226315B2 (ja) * | 2013-04-11 | 2017-11-08 | 国立大学法人高知大学 | 炎症性疾患の予防・治療剤、並びに炎症性疾患予防・治療薬のスクリーニング方法 |
| WO2014197339A1 (en) | 2013-06-08 | 2014-12-11 | Apple Inc. | Device, method, and graphical user interface for synchronizing two or more displays |
| CN103926413A (zh) * | 2014-04-28 | 2014-07-16 | 刘红莉 | 一种用尿液进行癌症快速检测的试剂条的制备方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10438929B2 (en) * | 2014-09-17 | 2019-10-08 | Toshiba Memory Corporation | Semiconductor device |
| JP6675605B2 (ja) * | 2014-10-10 | 2020-04-01 | 国立大学法人高知大学 | 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価 |
| WO2016110782A1 (en) | 2015-01-05 | 2016-07-14 | University Of Oslo | Prostate cancer markers and uses thereof |
| GB201503438D0 (en) * | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR102002866B1 (ko) * | 2016-07-28 | 2019-07-23 | 인하대학교 산학협력단 | Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR102661295B1 (ko) * | 2021-01-22 | 2024-04-30 | 기초과학연구원 | 탈당화된 lrg1 당단백질 및 lrg1 당단백질 변이체, 및 이의 용도 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| EP0828849B1 (en) | 1995-06-02 | 2006-10-25 | Gilead Sciences, Inc. | High-affinity oligonucleotide ligands to pdgf |
| WO2000001410A1 (en) * | 1998-07-06 | 2000-01-13 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| US20050064516A1 (en) | 2003-09-18 | 2005-03-24 | Kantor Aaron B. | Biological markers for diagnosing multiple sclerosis |
| MY164457A (en) * | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
| US7416850B2 (en) | 2006-01-25 | 2008-08-26 | Jemmerson Ronald R | Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies |
| CA2663878A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| JP2010504955A (ja) * | 2006-09-28 | 2010-02-18 | メルク セローノ ソシエテ アノニム | 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法 |
| AU2007333106A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
| US20090175827A1 (en) * | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008092214A1 (en) | 2007-02-02 | 2008-08-07 | Minomic International Limited | Biomarkers for diabetes |
| AU2008261951A1 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | miR-34 regulated genes and pathways as targets for therapeutic intervention |
| WO2009033581A1 (en) * | 2007-09-14 | 2009-03-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted tricyclic compounds and methods of use thereof |
| MX344733B (es) * | 2007-11-09 | 2017-01-04 | Genentech Inc * | Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina. |
| WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| WO2011015602A2 (en) | 2009-08-04 | 2011-02-10 | Biosystems International Sas | Lung cancer biomarkers |
-
2009
- 2009-09-04 GB GBGB0915515.1A patent/GB0915515D0/en not_active Ceased
-
2010
- 2010-09-06 AU AU2010290986A patent/AU2010290986B2/en active Active
- 2010-09-06 EP EP10754361.3A patent/EP2473526B1/en active Active
- 2010-09-06 CN CN201080039413.0A patent/CN102596998B/zh active Active
- 2010-09-06 US US13/393,531 patent/US8790647B2/en active Active
- 2010-09-06 WO PCT/GB2010/001681 patent/WO2011027129A1/en not_active Ceased
- 2010-09-06 ES ES10754361.3T patent/ES2647359T3/es active Active
- 2010-09-06 JP JP2012527383A patent/JP2013503621A/ja active Pending
- 2010-09-06 CA CA2771965A patent/CA2771965C/en active Active
-
2014
- 2014-06-23 US US14/312,593 patent/US9708397B2/en active Active
-
2015
- 2015-12-11 JP JP2015241950A patent/JP6242847B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503621A5 (enExample) | ||
| JP6856694B2 (ja) | Ｔｉｍ−３に対する抗体分子およびその使用 | |
| JP6676584B2 (ja) | ポリペプチドワクチン | |
| JP6423357B2 (ja) | 二重特異性ＥＧＦＲ／ｃ−Ｍｅｔ抗体 | |
| Yarden et al. | The ERBB network: at last, cancer therapy meets systems biology | |
| CN102596998B (zh) | 血管增殖病症的治疗 | |
| De Falco | Antiangiogenesis therapy: an update after the first decade | |
| KR102659538B1 (ko) | 자극성 및 비자극성 골수성 세포의 조절 | |
| ES2826774T3 (es) | Anticuerpo que se une a ERBB-2 y ERBB-3 | |
| JP6470849B2 (ja) | ニューロピリン１特異的結合ペプチド及びこのペプチドが融合された融合タンパク質及びその用途 | |
| ES2796090T3 (es) | Uso de moduladores MCOLN-1 para regular la migración celular | |
| AU2013347952A1 (en) | EGFR and c-Met-fibronectin type III domain binding molecules | |
| JP2015529641A5 (enExample) | ||
| WO2015109898A1 (zh) | VEGF与PDGFRβ双特异性融合蛋白及其用途 | |
| JP2015516370A5 (enExample) | ||
| JP2016536330A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| RU2014118739A (ru) | Способы ингибирования роста опухоли путем антагонизирования ил-6 рецептора | |
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| JP2014534237A5 (enExample) | ||
| CN105007939B (zh) | 人抗vegfr-2/kdr抗体 | |
| CN102239178A (zh) | 抑制p1gf以治疗费城染色体阳性白血病 | |
| WO2019114793A1 (zh) | 一种egfr抗体及其制备方法和应用 | |
| US20230151118A1 (en) | Artc1 ligands for cancer treatment | |
| CN103739710B (zh) | 一种抗vegf抗体及其应用 |